vic-1911,sotorasib
vitrac therap,amgen
['lung', 'sotorasib', 'vic-1911']
vitrac therapeutics to present phase 1 clinical trial design on novel aurora kinase a inhibitor, vic-1911, and g12c inhibitor, sotorasib, for kras g12c-mutant non-small cell lung cancer at the 2023 asco annual meeting 
Breaking news from Business Wire